This topic contains a solution. Click here to go to the answer

Author Question: When using a holding chamber with a metered-dose inhaler (MDI), you should tell the patient: A) ... (Read 76 times)

burton19126

  • Hero Member
  • *****
  • Posts: 532
When using a holding chamber with a metered-dose inhaler (MDI), you should tell the patient:
 A) Inhale as deeply and rapidly as you can when you squeeze the MDI.
  B) Squeeze the MDI when you exhale.
  C) Open your mouth and place the mouthpiece a few centimeters away.
  D) Place the mouthpiece in your mouth and inhale slowly when you squeeze.

Question 2

The first shunt encountered after blood enters the fetal abdominal cavity is the
 A) ductus venosus
  B) foramen ovale
  C) inferior vena cava
  D) superior vena cava



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

carolinefletcherr

  • Sr. Member
  • ****
  • Posts: 313
Answer to Question 1

D

Answer to Question 2

A




burton19126

  • Member
  • Posts: 532
Reply 2 on: Jul 16, 2018
Excellent


mjenn52

  • Member
  • Posts: 351
Reply 3 on: Yesterday
Wow, this really help

 

Did you know?

Certain topical medications such as clotrimazole and betamethasone are not approved for use in children younger than 12 years of age. They must be used very cautiously, as directed by a doctor, to treat any child. Children have a much greater response to topical steroid medications.

Did you know?

For about 100 years, scientists thought that peptic ulcers were caused by stress, spicy food, and alcohol. Later, researchers added stomach acid to the list of causes and began treating ulcers with antacids. Now it is known that peptic ulcers are predominantly caused by Helicobacter pylori, a spiral-shaped bacterium that normally exist in the stomach.

Did you know?

Women are 50% to 75% more likely than men to experience an adverse drug reaction.

Did you know?

Cytomegalovirus affects nearly the same amount of newborns every year as Down syndrome.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library